Samjin Pharmaceuticals Co., Ltd. (KRX:005500)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,540
-340 (-1.80%)
Mar 3, 2026, 3:30 PM KST
3.81%
Market Cap 231.43B
Revenue (ttm) 274.03B
Net Income (ttm) 21.89B
Shares Out 12.26M
EPS (ttm) 1,727.82
PE Ratio 10.93
Forward PE 11.34
Dividend 800.00 (4.24%)
Ex-Dividend Date Dec 29, 2025
Volume 49,270
Average Volume 39,721
Open 18,690
Previous Close 18,880
Day's Range 18,460 - 18,720
52-Week Range 16,590 - 21,300
Beta 0.15
RSI 38.29
Earnings Date Feb 3, 2026

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin... [Read more]

Sector Healthcare
Founded 1968
Employees 586
Stock Exchange Korea Stock Exchange
Ticker Symbol 005500
Full Company Profile

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.

Financial Statements

News

There is no news available yet.